Beysens M, Tailly TO. Ureteral stents in urolithiasis. Asian J Urol.
2018;5(4):274–86.
Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization
of urinary symptoms in patients with ureteral stents. Urology.
2002;59:511–16.
Bolat MS, Akdeniz E, Asci R, Erdemir F, Cinar O, Tomak L.
Ureterorenoscopy with stenting and its effect on male sexual function:
a controlled randomised prospective study. Andrologia.
2017;49(9):10.1111/and.12746.
Miyaoka R, Monga M. Ureteral stent discomfort: etiology and
management. Indian J Urol. 2009;25:455–460
Vega Vega A, García Alonso D, García Alonso CJ. Characterization of
urinary tract symptoms and quality of life in patients with
double-pig-tailed ureteral stents. Actas Urol Esp. 2007;31:738–42.
Joshi HB, Newns N, Stainthorpe A, Mac-Donagh RP, Keeley FX Jr, Timoney
AG. Ureteral stent symptom questionnaire: development and validation
of a multidimensional quality of life measure. J Urol. 2003;169:1060.
Tanidir Y, Mangir N, Sahan A, Sulukaya M. Turkish version of the
ureteral stent symptoms questionnaire: linguistic and psychometric
validation. World J Urol. 2017;35:1149–54.
Palmer CJ, Choi JM. Pathophysiology of overactive bladder: current
understanding. Curr Bladder Dysfunct Rep. 2017;12:74–9.
Thiagamoorthy G, Cardozo L, Robinson D. Current and future
pharmacotherapy for treating overactive bladder. Expert Opin
Pharmacother. 2016;17(10):1317–25.
Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P. Is there a role
for α-blockers in ureteral stent related symptoms? A systematic review
and meta-analysis. J Urol. 2011;186:928–34.
Zhou L, Cai X, Li H, Wang KJ. Effects of α-blockers, antimuscarinics,
or combination therapy in relieving ureteral stent-related symptoms: a
meta-analysis. J Endourol. 2015;29:650–6.
Cui Y, ZongH, YangC, YanH, Zhang Y. The efficacy and safety of
mirabegron in treating OAB: a systematic review and meta-analysis of
phase III trials. Int Urol Nephrol. 2014;46:275–84.
Warren K, Burden H, Abrams P. Mirabegron in overactive bladder
patients: efficacy review and update on drug safety. Ther Adv Drug
Saf. 2016;7:204–16.
Giannarini G, Keeley Jr FX, Valent F, et al. Predictors of morbidity
in patients with indwelling ureteric stents: results of a prospective
study using the validated ureteric stent symptoms questionnaire. BJU
Int. 2011;107:648–54.
Calvert RC, Wong KY, Chitale SV, et al. Multi-length or 24 cm ureteric
stent? A multicentre randomised comparison of stent-related symptoms
using a validated questionnaire. BJU Int. 2013;111:1099–104.
Nestler S, Witte B, Schilchegger L, Jones J. Size does matter:
ureteral stents with a smaller diameter show advantages regarding
urinary symptoms, pain levels and general health. World J Urol.
2020;38(4):1059-1063.
Deliveliotis K, Papatsoris AG, Skolarikos A, Mitsogiannis I, Tzannis
K, Dellis AE. Management of stent-related symptoms with the use of
α-blockers: a meta-analysis. Arab J Urol. 2019;18(1):14–21.
Otsuki H, Yamasaki T, Hori S, et al. The efficacy of mirabegron for
the relief of ureteral stent-related symptoms. Acta Med Okayama.
2020;74(2):145–50.
Tae BS, Cho S, Jeon BJ, et al. Does mirabegron relieve ureteric
stent-related discomfort? A prospective, randomized, multicentre
study. BJU Int. 2018;122(5):866–72.
Sahin A, Yildirim C, Yuksel OH, Urkmez A. Treatment of ureteral
catheter related symptoms; mirabegron versus tamsulosin/solifenacin
combination: a randomized controlled trial. Tratamiento de los
sintomas relacionados con los catéteres: mirabegon vs
tamsulosina-solifenacina en combinación: un estudio prospectivo
randomizado. Arch Esp Urol. 2020;73(1):54–9.
Yavuz A, Kilinc MF, Aydin M, Ofluoglu Y, Bayar G. Does tamsulosin or
mirabegron improve ureteral stent-related symptoms? A prospective
placebo-controlled study [published online ahead of print, 2020 May
14]. Low Urin Tract Symptoms. 2020;10.1111/luts.12320.
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry
MJ. Indwelling ureteral stents: evaluation of symptoms, quality of
life and utility. J Urol. 2003;169:1065–9.
Lang RJ, Davidson ME, Exintaris B. Pyeloureteral motility and ureteral
peristalsis: essential role of sensory nerves and endogenous
prostaglandins. Exp Physiol. 2002;87:129–46.
Wang J, Zhang X, Zhang T, Mu J, Bai B, Lei Y. The role of solifenacin,
as monotherapy or combination with tamsulosin in ureteral
stent-related symptoms: a systematic review and meta-analysis. World J
Urol. 2017;35(11):166980.
Yan H, Wang Y, Sun R, Cui Y. The efficacy of antimuscarinics alone or
in combination with alpha-blockers for the treatment of ureteral
stent-related symptoms: a systematic review and meta-analysis. Urol
Int. 2017;99(1):6–13.
Matsumoto R, Otsuka A, Suzuki T, et al. Expression and functional role
of β3-adrenoceptors in the human ureter. Int J Urol.
2013;20(10):1007–14.
Shen H, Chen Z, Mokhtar AD et al. Expression of beta-adrenergic
receptor subtypes in human normal and dilated ureter. Int Urol
Nephrol. 2017;49:1771–8.
Akdeniz E, Bolat MS. Ureterorenoscopy with stenting and its effect on
female sexual function. Urol J. 2017;14:3059e63.
Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A,
Varkarakis IM. Is there a role for alpha1-blockers in treating
double-J stent-related symptoms? Urology. 2006;67:35–9.
Maldonado-Avila M, Garduno-Arteaga L, Jungfermann-Guzman R, et al.
Efficacy of tamsulosin, oxybutynin, and their combination in the
control of double-j stent-related lower urinary tract symptoms. Int
Braz J Urol. 2016;42(3):487–93.
Figure Legends:Figure 1. The study design.Table 1. Demographic features.Table 2. USSQ scores.